REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 149 filers reported holding REATA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.53 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $258,852,989 | +28.8% | 2,538,770 | +14.9% | 0.01% | +16.7% |
| Q1 2023 | $200,910,380 | +111.4% | 2,209,749 | -11.7% | 0.01% | +100.0% |
| Q4 2022 | $95,049,383 | +51.6% | 2,501,958 | +0.3% | 0.00% | +50.0% |
| Q3 2022 | $62,709,000 | -4.5% | 2,495,371 | +15.5% | 0.00% | 0.0% |
| Q2 2022 | $65,631,000 | -3.5% | 2,159,647 | +4.0% | 0.00% | 0.0% |
| Q1 2022 | $68,002,000 | +22.0% | 2,075,760 | -1.8% | 0.00% | +100.0% |
| Q4 2021 | $55,748,000 | -73.9% | 2,114,050 | -0.3% | 0.00% | -83.3% |
| Q3 2021 | $213,366,000 | -29.4% | 2,120,722 | -0.7% | 0.01% | -25.0% |
| Q2 2021 | $302,275,000 | +104.3% | 2,135,771 | +43.9% | 0.01% | +100.0% |
| Q1 2021 | $147,954,000 | -15.4% | 1,483,998 | +4.8% | 0.00% | -33.3% |
| Q4 2020 | $174,986,000 | +30.5% | 1,415,513 | +2.9% | 0.01% | +20.0% |
| Q3 2020 | $134,058,000 | -46.5% | 1,376,084 | -14.4% | 0.01% | -50.0% |
| Q2 2020 | $250,681,000 | -18.2% | 1,606,730 | -24.3% | 0.01% | -33.3% |
| Q1 2020 | $306,489,000 | -33.2% | 2,123,379 | -5.4% | 0.02% | -16.7% |
| Q4 2019 | $458,712,000 | +192.2% | 2,243,871 | +14.8% | 0.02% | +157.1% |
| Q3 2019 | $156,986,000 | -13.1% | 1,955,230 | +2.1% | 0.01% | -12.5% |
| Q2 2019 | $180,747,000 | +13.9% | 1,915,707 | +3.2% | 0.01% | +14.3% |
| Q1 2019 | $158,704,000 | +44.5% | 1,856,854 | -5.2% | 0.01% | +16.7% |
| Q4 2018 | $109,851,000 | -30.3% | 1,958,164 | +1.5% | 0.01% | -14.3% |
| Q3 2018 | $157,663,000 | +199.8% | 1,928,362 | +28.2% | 0.01% | +250.0% |
| Q2 2018 | $52,587,000 | +115.1% | 1,503,780 | +26.2% | 0.00% | +100.0% |
| Q1 2018 | $24,444,000 | -28.3% | 1,191,856 | -1.0% | 0.00% | -50.0% |
| Q4 2017 | $34,099,000 | +22.3% | 1,203,993 | +34.3% | 0.00% | +100.0% |
| Q3 2017 | $27,877,000 | +92.2% | 896,357 | +95.5% | 0.00% | 0.0% |
| Q2 2017 | $14,505,000 | +81.4% | 458,483 | +29.9% | 0.00% | – |
| Q1 2017 | $7,996,000 | +159820.0% | 353,017 | +161834.4% | 0.00% | – |
| Q4 2016 | $5,000 | -16.7% | 218 | 0.0% | 0.00% | – |
| Q3 2016 | $6,000 | -92.2% | 218 | -94.4% | 0.00% | – |
| Q2 2016 | $77,000 | – | 3,877 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |